Oxaliplatin-induced increase in splenic volume: experiences from multicenter study in Japan.

Ryo OhtaTakeshi YamadaKeisuke HaraTakuma IwaiKohji TanakayaKeiichiro IshibashiKazuhiko YoshimatsuChihiro KosugiMasahiro TsubakiHideo NakajimaMasatoshi OyaHiroshi YoshidaKeiji KodaHideyuki Ishida

Published in: International journal of clinical oncology (2020)

This study can be verified the findings observed in our previous single-center study, oxaliplatin-based adjuvant chemotherapy was associated with an increase in SV. Furthermore, this increase can persist for > 1 year. The continuous presence of SOS may have a negative impact on prognosis in patients that develop recurrent disease.

Keyphrases

end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
prognostic factors
peritoneal dialysis
mental health
high glucose
endothelial cells
patient reported